JPMorgan Starts Alder Biopharm (ALDR) at Overweight
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
JPMorgan initiated coverage on Alder Biopharm (NASDAQ: ALDR) with an Overweight rating and a price target of $40.00.
Shares of Alder Biopharm closed at $31.25 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RCI Hospitality Holdings (RICK) Gains as Sidoti & Co. Sets Aggressive Price Target
- Alder BioPharma (ALDR) Commences Second Pivotal Eptinezumab Phase 3 in Migraines
- Seaport Global Securities Starts WGL Holdings (WGL) at Neutral
Create E-mail Alert Related CategoriesHot New Coverage, New Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!